Dr. Rex is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. He is currently CMO for F2G, Ltd. (an antifungal biotech), sits on two biotech boards (F2G Ltd, Adenium Biotech ApS), is an Expert-in-Residence for Wellcome Trust, is an operating partner with a venture capital group (Advent Life Sciences), and is a voting member on the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB). He also blogs regularly at http://amr.solutions/blog.html.
His experience (figure) includes moving compounds from early preclinical development through all development phases via academic positions (NIH, Bethesda, MD; Univ. of Texas Medical School-Houston) and VP-level roles at a multinational pharmaceutical firm (AstraZeneca). Other past activities include advancing novel regulatory paradigms for antibacterial agents,1,2 publications on novel reimbursement models for antibiotics,3 co-founding of a public-private partnership (CARB-X), co-founding of the New Drugs for Bad Bugs (ND4BB) program of Europe’s Innovative Medicines Initiative (IMI), and a 4-year term as Industry Representative on the FDA Anti-Infective Drugs Advisory Committee (AIDAC, 2007–2011).
1) Rex JH et al. Proposal for a comprehensive regulatory framework to address the unmet need for new antibacterial therapies. Lancet ID 13:269-275, 2013.
2) Rex, JH et al. Progress in the fight against multidrug-resistant bacteria 2005-2016: Modern non-inferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clinical Infectious Diseases 65:141-146, 2017.
3) Rex, J. H. and K. Outterson Antibiotic Reimbursement in a Sales-Delinked Model: Context and a Benchmark-Based Global Approach. Lancet ID 16:500-5, 2016.